|
|
||||||||




* Department of Surgery,
Department of Microbiology and Immunology, and
Department of Pathology University of Maryland Medical School, Baltimore, MD 21201
Immune destruction of the graft renal tubules is an important barrier to the long-term function of clinical renal allografts, but the underlying mechanisms remain obscure. CD103an integrin conferring specificity for the epithelial cell-restricted ligand, E-cadherindefines a subset of CD8 effectors that infiltrate the graft tubular epithelium during clinical rejection episodes, predicting a causal role for CD103+CD8+ effectors in tubular injury. In the present study, we used rodent transplant models to directly test this hypothesis. Surprisingly, CD8 cells infiltrating renal allografts undergoing unmodified acute rejection did not express significant levels of CD103. However, we demonstrate that a brief course of cyclosporine A to rat renal allograft recipients promotes progressive accumulation of CD103+CD8+ cells within the graft, concomitant with the development of tubular atrophy and interstitial fibrosis. As in the known clinical scenario, graft-associated CD103+CD8+ cells exhibited a T effector phenotype and were intimately associated with the renal tubular epithelium. Treatment with anti-CD103 mAb dramatically attenuated CD8 infiltration into the renal tubules and tubular injury. Mouse studies documented that CD103 expression is required for efficient destruction of the graft renal tubules by CD8 effectors directed to donor MHC I alloantigens. Taken together, these data document a causal role for CD103+CD8+ effectors in promoting tubular injury following allogeneic renal transplantation and identify novel targets for therapeutic intervention in this important clinical problem.
This article has been cited by other articles:
![]() |
A. A. Pozdzik, I. J. Salmon, C. P. Husson, C. Decaestecker, E. Rogier, M.-F. Bourgeade, M. M. Deschodt-Lanckman, J.-L. Vanherweghem, and J. L. Nortier Patterns of interstitial inflammation during the evolution of renal injury in experimental aristolochic acid nephropathy Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2480 - 2491. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Schlickum, H. Sennefelder, M. Friedrich, G. Harms, M. J. Lohse, P. Kilshaw, and M. P. Schon Integrin {alpha}E(CD103){beta}7 influences cellular shape and motility in a ligand-dependent fashion Blood, August 1, 2008; 112(3): 619 - 625. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. H. Horne, M. A. Koester, K. Jayashankar, K. E. Lunsford, H. L. Dziema, and G. L. Bumgardner Disparate Primary and Secondary Allospecific CD8+ T Cell Cytolytic Effector Function in the Presence or Absence of Host CD4+ T Cells J. Immunol., July 1, 2007; 179(1): 80 - 88. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Waeckerle-Men, A. Starke, and R. P. Wuthrich PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+cytotoxic T cells Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1527 - 1536. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Floc'h, A. Jalil, I. Vergnon, B. L. M. Chansac, V. Lazar, G. Bismuth, S. Chouaib, and F. Mami-Chouaib {alpha}E{beta}7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis J. Exp. Med., March 19, 2007; 204(3): 559 - 570. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-L. Ling, N. Dulphy, P. Bahl, M. Salio, K. Maskell, J. Piris, B. F. Warren, B. D. George, N. J. Mortensen, and V. Cerundolo Modulation of CD103 Expression on Human Colon Carcinoma-Specific CTL J. Immunol., March 1, 2007; 178(5): 2908 - 2915. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Ivakine, S. M. Mortin-Toth, O. M. Gulban, A. Valova, A. Canty, C. Scott, and J. S. Danska The Idd4 Locus Displays Sex-Specific Epistatic Effects on Type 1 Diabetes Susceptibility in Nonobese Diabetic Mice Diabetes, December 1, 2006; 55(12): 3611 - 3619. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Uss, A. T. Rowshani, B. Hooibrink, N. M. Lardy, R. A. W. van Lier, and I. J. M. ten Berge CD103 Is a Marker for Alloantigen-Induced Regulatory CD8+ T Cells. J. Immunol., September 1, 2006; 177(5): 2775 - 2783. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |